Last mentioned: Mar 4, 2026
Cibotercept Data
Anticipated top-line data from the Phase 2 TROPOS trial in PAH patients.
FY 2025 Earnings
Official reporting of full-year financial results and 2026 clinical guidance.
KER-050 Expansion
Initiation of the global Phase 2/3 trial for elritercept in lower-risk MDS.
Capital Infusion
Keros raised $140 million in a follow-on offering to fund late-stage TGF-beta trials.
Keros Therapeutics reported robust fourth-quarter and full-year 2025 financial results, highlighting significant clinical progress across its TGF-β superfamily pipeline. The company remains well-capitalized to advance its lead assets, elritercept and cibotercept, through critical Phase 2 and Phase 3 milestones in 2026.
This page surfaces every story mentioning Keros Therapeutics across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Keros Therapeutics was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |